Cargando…

Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope

To relieve the limitations of the human papillomavirus (HPV) vaccines based on L1 capsid protein, vaccine formulations based on RG1 epitope of HPV L2 using various built-in adjuvants are under study. Herein, we describe design and construction of a rejoined peptide (RP) harboring HPV16 RG1 epitope f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mashhadi Abolghasem Shirazi, Maryam, Sadat, Seyed Mehdi, Haghighat, Setareh, Roohvand, Farzin, Arashkia, Arash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556035/ https://www.ncbi.nlm.nih.gov/pubmed/37798448 http://dx.doi.org/10.1038/s41598-023-43965-3

Ejemplares similares

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
por: Zhou, Shi-Hao, et al.
Publicado: (2022)

Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
por: Dorostkar, Fariba, et al.
Publicado: (2021)

Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies
por: Khiavi, Farhad Motavalli, et al.
Publicado: (2017)

A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine
por: Tzeng, Tsai-Teng, et al.
Publicado: (2023)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma
por: Hajiabadi, Sare, et al.
Publicado: (2023)

Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease
por: Yu, Xiaocong, et al.
Publicado: (2013)

Trial watch: TLR3 agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

OMV Vaccines and the Role of TLR Agonists in Immune Response
por: Mancini, Francesca, et al.
Publicado: (2020)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

TLR Agonist Therapy of Metastatic Breast Cancer in Mice
por: Klinman, Dennis M., et al.
Publicado: (2023)

A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice
por: Motavalli Khiavi, Farhad, et al.
Publicado: (2018)

TLR3 and TLR9 Agonists Improve Postexposure Vaccination Efficacy of Live Smallpox Vaccines
por: Israely, Tomer, et al.
Publicado: (2014)

Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists
por: Lacerte, Patricia, et al.
Publicado: (2016)

TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN
por: Temizoz, Burcu, et al.
Publicado: (2015)

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation
por: Zhang, Bo-Dou, et al.
Publicado: (2022)

The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
por: Koido, Shigeo, et al.
Publicado: (2013)

Development of N-Acetylated Dipalmitoyl-S-Glyceryl Cysteine Analogs as Efficient TLR2/TLR6 Agonists
por: Zhou, Yang, et al.
Publicado: (2019)

Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8
por: Wang, Xiaoyu, et al.
Publicado: (2022)

Cytokine Effect of TLR3, TLR4, and TLR7 Agonists Alone or Associated with Leishmania infantum Antigen on Blood from Dogs
por: Martínez-Orellana, Pamela, et al.
Publicado: (2018)

Differential Response of Gestational Tissues to TLR3 Viral Priming Prior to Exposure to Bacterial TLR2 and TLR2/6 Agonists
por: Rasheed, Zahirrah B. M., et al.
Publicado: (2020)

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
por: Luchner, Marina, et al.
Publicado: (2021)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

A Chemically Defined TLR3 Agonist with Anticancer Activity
por: Le Naour, Julie, et al.
Publicado: (2023)

Innate Immune Receptors in Human Airway Smooth Muscle Cells: Activation by TLR1/2, TLR3, TLR4, TLR7 and NOD1 Agonists
por: Månsson Kvarnhammar, Anne, et al.
Publicado: (2013)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism
por: Noack, J, et al.
Publicado: (2012)

Chronic Exposure of Gingival Fibroblasts to TLR2 or TLR4 Agonist Inhibits Osteoclastogenesis but Does Not Affect Osteogenesis
por: Karlis, Gerasimos D., et al.
Publicado: (2020)

The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants
por: Naushad, Shaik Mohammad, et al.
Publicado: (2023)

Isolation, cloning, and expression of E. coli BirA gene for biotinylation applications
por: Etemadzadeh, Mohammad Hossein, et al.
Publicado: (2015)

The β‐domain of streptokinase affects several functionalities, including specific/proteolytic activity kinetics
por: Rafipour, Maryam, et al.
Publicado: (2019)

Contribution of Streptokinase-Domains from Groups G and A (SK2a) Streptococci in Amidolytic/Proteolytic Activities and Fibrin-Dependent Plasminogen Activation: A Domain-Exchange Study
por: Rafipour, Maryam, et al.
Publicado: (2020)

Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer
por: Shukla, Nikunj M., et al.
Publicado: (2012)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Modulation of Innate Immune Responses via Covalently Linked TLR Agonists
por: Tom, Janine K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vihim41bbutgiquu7b66io2rlc